Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns
Movement Disorders
P15 - Poster Session 15 (12:00 PM-1:00 PM)
3-017
To carry out a cost-analysis based on the respective recommended dosing per muscle using IncobotulinumtoxinA (INCO) and AbobotulinumtoxinA (ABO) for the treatment of post-stroke upper limb spasticity (PSULS). 

Data related to the comparative cost of PSULS treatment with INCO vs ABO is scarce.
Recommended doses per muscle were extracted from both Canadian product monographs and the dose conversion ratios (lower and upper ranges) were calculated. Overall cumulative botulinumtoxinA (BoNT-A) costs over a period of 5 years were calculated using BoNT-A costs drawn from Canadian public databases. The assumptions were made that 3-month treatment cycles were used and that all other post-stroke management-associated costs remained the same for both BoNT-A products (i.e., administration cost, caregiver cost, hospital cost, work absenteeism, etc.). To minimize waste of BoNT-A products, the most efficient combination of vials was selected. 
The calculated INCO:ABO conversion ratio was 1:4.25. Based on a dose of 400U of INCO and current BoNT-A products costs, the cumulative costs ($CAD) of a 5 year treatment regimen is 26,400$ for INCO and 46,231$ for ABO (equivalent dose of 1700U). As per ABO’s Canadian product monograph, the maximum dose is 1500U. In this case, the cumulative costs over a period of 5 years is 38,520$. Similar cumulative costs were obtained when calculation was performed using the conversion ratio determined from the average dose per clinical patterns (1:4.21). 
According to the clinical conversion ratio of 1:4.25, INCO is more cost-effective than ABO in PSULS.   
Authors/Disclosures
Marie-Eve Gendron
PRESENTER 		Marie-Eve Gendron has received personal compensation for serving as an employee of Merz Therapeutics.
Denis Vezina, PhD (Hoechst-Marian Roussel) No disclosure on file